Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STING1 | Q86WV6 | 18/20 | 0.61 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.55 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.55 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.55 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.55 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.55 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.55 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.55 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.55 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.55 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.55 |
| ▸ | ACHE | P22303 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20022236 | 0.89 | STING1 (0.67) | STING1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL29636404 | 0.89 | STING1 (0.67) | STING1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL29636390 | 0.87 | STING1 (0.64) | STING1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL21452735 | 0.87 | STING1 (0.49) | STING1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL20022264 | 0.87 | STING1 (0.64) | STING1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL20022240 | 0.87 | STING1 (0.61) | STING1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL9204578 | 0.84 | STING1 (0.63) | STING1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL1589579 | 0.84 | STING1 (0.68) | STING1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL21405857 | 0.83 | STING1 (0.54) | STING1ACHE | |
| SCHEMBL7106760 | 0.83 | STING1 (0.61) | STING1HDAC3HDAC4HDAC1HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3774764-A1 | BENZOTHIOPHENES AND RELATED COMPOUNDS AS STING AGONISTS | Merck Sharp&Dohme Corp. (US) | 2021-02-17 | — | — | EP | disclosed |
| CN-111971277-A | Benzothiophenes and related compounds as STING agonists | 默沙东公司 | 2020-11-20 | — | — | CN | disclosed |
| US-10793557-B2 | Sting agonist compounds | MERCK SHARP & DOHME CORP. (US) | 2020-10-06 | — | — | US | disclosed |
| US-10793557-B2 | Sting agonist compounds | MERCK SHARP & DOHME CORP. (US) | 2020-10-06 | — | — | US | disclosed |
| US-10730849-B2 | Benzo[b]thiophene compounds as STING agonists | MERCK SHARP & DOHME CORP. (US) | 2020-08-04 | — | — | US | disclosed |
| US-10730849-B2 | Benzo[b]thiophene compounds as STING agonists | MERCK SHARP & DOHME CORP. (US) | 2020-08-04 | — | — | US | disclosed |
| US-10703738-B2 | Benzo[b]thiophene compounds as STING agonists | MERCK SHARP & DOHME CORP. (US) | 2020-07-07 | — | — | US | disclosed |
| US-10703738-B2 | Benzo[b]thiophene compounds as STING agonists | MERCK SHARP & DOHME CORP. (US) | 2020-07-07 | — | — | US | disclosed |
| US-20190337918-A1 | BENZO[b]THIOPHENE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2019-11-07 | — | — | US | disclosed |
| US-20190337917-A1 | BENZO[b]THIOPHENE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2019-11-07 | — | — | US | disclosed |
| US-20180093964-A1 | BENZO[b]THIOPHENE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2018-04-05 | — | — | US | disclosed |
| US-20180093964-A1 | BENZO[b]THIOPHENE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2018-04-05 | — | — | US | disclosed |
| EP-2947073-A2 | FUSED RING ANALOGUES OF ANTI-FIBROTIC AGENTS | Fibrotech Therapeutics Pty Ltd (AU) | 2015-11-25 | — | — | EP | disclosed |
| US-20150266893-A1 | FUSED RING ANALOGUES OF ANTI-FIBROTIC AGENTS | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2015-09-24 | — | — | US | disclosed |
| EP-2491030-B1 | FUSED RING ANALOGUES OF ANTI-FIBROTIC AGENTS | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2015-07-15 | — | — | EP | disclosed |
| US-9062076-B2 | Fused ring analogues of anti-fibrotic agents | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2015-06-23 | — | — | US | disclosed |
| US-20130338151-A9 | FUSED RING ANALOGUES OF ANTI-FIBROTIC AGENTS | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2013-12-19 | — | — | US | disclosed |
| US-20120270863-A1 | FUSED RING ANALOGUES OF ANTI-FIBROTIC AGENTS | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2012-10-25 | — | — | US | disclosed |
| EP-2491030-A1 | FUSED RING ANALOGUES OF ANTI-FIBROTIC AGENTS | Fibrotech Therapeutics PTY LTD (AU) | 2012-08-29 | — | — | EP | disclosed |
| WO-2011047432-A1 | FUSED RING ANALOGUES OF ANTI-FIBROTIC AGENTS | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2011-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150266893-A1 | FUSED RING ANALOGUES OF ANTI-FIBROTIC AGENTS | MMP1, FIBP, COL2A1 | STING1 1767/4885HDAC3 134/4885HDAC4 244/4885 |
| US-20190337918-A1 | BENZO[b]THIOPHENE COMPOUNDS AS STING AGONISTS | STING1, IRF3, CGAS | STING1 1/4885HDAC3 4365/4885HDAC4 4443/4885 |
| US-20120270863-A1 | FUSED RING ANALOGUES OF ANTI-FIBROTIC AGENTS | MMP1, FIBP, COL2A1 | STING1 1767/4885HDAC3 134/4885HDAC4 244/4885 |
| US-10730849-B2 | Benzo[b]thiophene compounds as STING agonists | STING1, IRF3, CGAS | STING1 1/4885HDAC3 4365/4885HDAC4 4443/4885 |
| US-20180093964-A1 | BENZO[b]THIOPHENE COMPOUNDS AS STING AGONISTS | STING1, IRF3, CGAS | STING1 1/4885HDAC3 4365/4885HDAC4 4443/4885 |
| US-10793557-B2 | Sting agonist compounds | STING1, CGAS, IRF3 | STING1 1/4885HDAC3 4824/4885HDAC4 4239/4885 |
| US-20130338151-A9 | FUSED RING ANALOGUES OF ANTI-FIBROTIC AGENTS | MMP1, FIBP, COL2A1 | STING1 1767/4885HDAC3 134/4885HDAC4 244/4885 |
| US-20190337917-A1 | BENZO[b]THIOPHENE COMPOUNDS AS STING AGONISTS | STING1, IRF3, CGAS | STING1 1/4885HDAC3 4365/4885HDAC4 4443/4885 |
| US-10703738-B2 | Benzo[b]thiophene compounds as STING agonists | STING1, IRF3, CGAS | STING1 1/4885HDAC3 4365/4885HDAC4 4443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.